ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q2 2022. The put-call ratio across all filers is 0.47 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,186,232 | -7.8% | 12,668 | -12.1% | 0.01% | 0.0% |
| Q2 2023 | $1,286,271 | -9.9% | 14,412 | +8.2% | 0.01% | -25.0% |
| Q1 2023 | $1,427,956 | -7.7% | 13,318 | +5.1% | 0.01% | -11.1% |
| Q4 2022 | $1,547,387 | +18.3% | 12,670 | 0.0% | 0.01% | +12.5% |
| Q3 2022 | $1,308,000 | +11.0% | 12,670 | 0.0% | 0.01% | +14.3% |
| Q2 2022 | $1,178,000 | -14.8% | 12,670 | +7.6% | 0.01% | -12.5% |
| Q1 2022 | $1,383,000 | -3.4% | 11,780 | +10.7% | 0.01% | +14.3% |
| Q4 2021 | $1,431,000 | -0.4% | 10,640 | +18.0% | 0.01% | -12.5% |
| Q3 2021 | $1,437,000 | +34.6% | 9,018 | +11.0% | 0.01% | +33.3% |
| Q2 2021 | $1,068,000 | +2.0% | 8,122 | 0.0% | 0.01% | -14.3% |
| Q1 2021 | $1,047,000 | – | 8,122 | – | 0.01% | – |
| Q4 2020 | $0 | – | 0 | – | 0.00% | – |
| Q3 2020 | $0 | – | 0 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |